We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-8.37%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.71B
AUM Growth
-$646M
Cap. Flow
+$138M
Cap. Flow %
3.73%
Top 10 Hldgs %
52.04%
Holding
130
New
26
Increased
23
Reduced
15
Closed
21

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$76.1M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$38.9M
3
FOLD
Amicus Therapeutics
FOLD
+$33.6M
4
AMRN
Amarin Corp
AMRN
+$25M
5
YMAB
Y-mAbs Therapeutics
YMAB
+$21.8M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$54.5M
2
ARRY
Array Biopharma Inc
ARRY
+$48.1M
3
BPMC
Blueprint Medicines
BPMC
+$28.5M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$24M
5
QURE icon
uniQure
QURE
+$22M

Sector Composition

Rank Sector Weight
1 Healthcare 93.8%
2 Financials 0.46%
3 Consumer Discretionary 0.18%
4 Technology 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
101
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$145K ﹤0.01%
+100,000
New +$9.39M
ABEOW
102
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
$145K ﹤0.01%
659,636
– –
CFMS
103
DELISTED
Conformis, Inc. Common Stock
CFMS
$93K ﹤0.01%
+2,000
New +$120K
OTLKW
104
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$48K ﹤0.01%
420,875
– –
ASND icon
105
Ascendis Pharma A/S
ASND
$16.5B
– –
-473,475
Closed -$54.5M
BHC icon
106
Bausch Health
BHC
$1.75B
– –
-600,000
Closed -$15.1M
BIIB icon
107
CALL
Biogen
BIIB
$30.9B
– –
-200,000
Closed -$65K
DXCM icon
108
DexCom
DXCM
$29B
– –
-240,000
Closed -$8.99M
GH icon
109
Guardant Health
GH
$19.1B
– –
-6,617
Closed -$571K
LAB icon
110
Standard BioTools
LAB
$342M
– –
-46,030
Closed -$567K
MCRB icon
111
Seres Therapeutics
MCRB
$45M
– –
-125,000
Closed -$8.05M
QURE icon
112
uniQure
QURE
$2.75B
– –
-281,820
Closed -$22M
RMTI icon
113
Rockwell Medical
RMTI
$27.2M
– –
-13,636
Closed -$4.51M
RYTM icon
114
Rhythm Pharmaceuticals
RYTM
$7.31B
– –
-262,970
Closed -$5.79M
SLDB icon
115
CALL
Solid Biosciences
SLDB
$792M
– –
-13
Closed -$23K
SYBX
116
DELISTED
Synlogic
SYBX
– –
-57,857
Closed -$7.9M
TCRT icon
117
Alaunos Therapeutics
TCRT
$4.64M
– –
-603
Closed -$528K
TDOC icon
118
Teladoc Health
TDOC
$1.66B
– –
-307,021
Closed -$20.4M
THC icon
119
Tenet Healthcare
THC
$22.2B
– –
-300,633
Closed -$6.21M
VYGR icon
120
Voyager Therapeutics
VYGR
$181M
– –
-36,573
Closed -$996K
AXNX
121
DELISTED
Axonics, Inc. Common Stock
AXNX
– –
-285,502
Closed -$11.7M
SWAV
122
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
– –
-150,000
Closed -$8.56M
ACOR
123
DELISTED
Acorda Therapeutics
ACOR
– –
-9,394
Closed -$8.65M
ARRY
124
DELISTED
Array Biopharma Inc
ARRY
– –
-1,038,390
Closed -$48.1M
1 2 3 4
5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2019 Portfolio in Review

As of Q3 2019, Perceptive Advisors held 130 positions worth $3.71B, down 15% from $4.36B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Perceptive Advisors deployed $138M of net new capital in Q3 2019, opening 26 new positions and adding to 23 existing holdings. Its largest new stake was SpringWorks Therapeutics: 3,217,522 shares worth $69.8M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Blueprint Medicines, an estimated $28.5M trimmed.

  • Perceptive Advisors's largest Q3 2019 buy was SpringWorks Therapeutics: 3,217,522 shares worth $69.8M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q3 2019, an estimated $38.9M increase.
  • Perceptive Advisors's biggest Q3 2019 reduction was Blueprint Medicines, cutting an estimated $28.5M.
  • Perceptive Advisors fully exited Ascendis Pharma A/S in Q3 2019, selling an estimated $54.5M.
  • Perceptive Advisors's ten largest holdings make up 52% of its $3.71B portfolio in Q3 2019.
  • Perceptive Advisors opened 26 new positions and closed 21 in Q3 2019.
  • Perceptive Advisors's portfolio value fell 15% quarter-over-quarter to $3.71B.

Based on Perceptive Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.